<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696718</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00303-52</org_study_id>
    <nct_id>NCT04696718</nct_id>
  </id_info>
  <brief_title>Determination of the Biological Activity of Serum From Patients</brief_title>
  <acronym>nutricell3</acronym>
  <official_title>Determination of the Biological Activity of Serum From Patients With Rheumatoid Arthritis After Consumption of Three Different Probiotics Strains (Lactobacillus Salivarius, Rhamnosus, Bifidobacterium Lactis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adeline BLOT</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Emile Roux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche en Nutrition Humaine d'Auvergne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Recherche Agronomique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to determine the influence of patient sera before and&#xD;
      after probiotic intervention on the behavior of bone cells (osteoblasts and osteoclasts).&#xD;
&#xD;
      The secondary objectives are to assess the activity of bone cells and the course of&#xD;
      rheumatoid arthritis before and after the consomption of probiotics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The written consent of the subjects will be obtained after full information of the aims,&#xD;
      nature and possible risks of the study.&#xD;
&#xD;
      Before inclusion, subjects will undergo a medical check-up including an interview on personal&#xD;
      and family history and drug treatments taken as well as a standard medical examination&#xD;
      including weight, height and blood pressure measurement. . Their compliance with the&#xD;
      inclusion / exclusion criteria will be verified during this review. An interview with&#xD;
      personnel involved in the research (a dietician / study Research clinic assistant, etc.) will&#xD;
      also be carried out as well as a biological selection assessment.&#xD;
&#xD;
      As part of this study, the subjects will come a total of 7 times to the Emile ROUX hospital&#xD;
      in Le Puy en Velay.&#xD;
&#xD;
      The probiotic treatment will begin between 1 and 3 weeks after the inclusion visit. The&#xD;
      volunteers / patients recruited will have a volume of blood sampled and a stool collected&#xD;
      before the start of the probiotic treatment (T = 0) and at the end of the treatment (T = 4&#xD;
      weeks). The study consists of three periods of probiotic treatment of 4 weeks each&#xD;
      interspersed with a wash-out period of 3 weeks in accordance with the recovery period&#xD;
      necessary between two blood samples.&#xD;
&#xD;
      The sera thus obtained will then be analyzed to determine their biological activity with&#xD;
      regard to the induction of changes in the behavior of bone cell models: osteoformin cells&#xD;
      (osteoblasts) and osteo-resorbent cells (osteoclasts).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2018</start_date>
  <completion_date type="Anticipated">December 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover Assignment patient may receive 3 products in 3 interventions sequentially during the protocol</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of biological activity of serum between day 0 to day 28</measure>
    <time_frame>Day 0 and Day 28</time_frame>
    <description>Ex vivo quantification of the formation of osteoclast multi-nucleated cells following culture in the presence of metabolites from the serum of patients between day 0 and day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Disease Activity Score (DAS28) day 0 to day 28</measure>
    <time_frame>Day 0 and Day 28</time_frame>
    <description>The Disease Activity Score (DAS) is a combined index to measure the disease activity in patients with rheumatoid arthritis (RA).&#xD;
Evaluation of a patient's response to treatment can be made much easier and more objective using the DAS28. (Twenty-eight tender and swollen joint scores include the same joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and the knees.) Simply assess the number of swollen and tender joints and measure the ESR. The DAS will provide you with a number between 0 and 10, indicating the activity rate of the rheumatoid arthritis is at that particular moment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Women</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Traitement 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus salivarius</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traitement 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus Rhamnosus GG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traitement 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium lactis</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>daily supplementation</intervention_name>
    <description>the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days</description>
    <arm_group_label>Traitement 1</arm_group_label>
    <arm_group_label>Traitement 2</arm_group_label>
    <arm_group_label>Traitement 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Women&#xD;
&#xD;
          -  30-75 years&#xD;
&#xD;
          -  Non-menopausal or menopausal for more than 2 years because the tissue osteoarticular&#xD;
             is under the influence of steroid hormones. Peri-menopause is accompanied by strong&#xD;
             hormonal variations.&#xD;
&#xD;
          -  With rheumatoid arthritis (DAS28 threshold specified below)&#xD;
&#xD;
          -  Clinical arthritis score â‰¥ 2.6 (DAS28). Pathology needs to be characterized even if&#xD;
             the score remains low&#xD;
&#xD;
          -  Person with good venous condition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Vaccination in the last two months&#xD;
&#xD;
          -  Alcohol abuse with regard to WHO standards&#xD;
&#xD;
          -  Smoking (&gt;5 cigarettes/day)&#xD;
&#xD;
             -&gt; 5 hours of intense sport per week&#xD;
&#xD;
          -  Food allergy and others&#xD;
&#xD;
          -  Antibiotic treatment in the month preceding inclusion&#xD;
&#xD;
          -  Persons under guardianship, curators, deprived of liberties, safeguard of justice&#xD;
&#xD;
          -  Refusal to sign the information and consent form&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>higher prevalency of RA in women</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>benjamin castagne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Emile Roux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yohann wittrant, PhD</last_name>
    <phone>+33682297271</phone>
    <email>yohann.wittrant@inrae.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>emilie gadea, PhD</last_name>
    <email>responsable.rechercheclinique@ch-lepuy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Emile Roux</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <zip>43000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>emile gadea, PhD</last_name>
      <email>responsable.rechercheclinique@ch-lepuy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut National de la Recherche Agronomique</investigator_affiliation>
    <investigator_full_name>Adeline BLOT</investigator_full_name>
    <investigator_title>Clinical Research Associate</investigator_title>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

